VRDN
HealthcareViridian Therapeutics, Inc. · Biotechnology · $2B
What is Viridian Therapeutics, Inc.?
Viridian Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based treatments for serious diseases, with a primary emphasis on thyroid eye disease. Headquartered in Waltham, Massachusetts, the company is advancing multiple candidates through early-stage clinical trials.
Viridian generates no commercial revenue yet — its business model centers on advancing a pipeline of monoclonal antibody therapies through clinical development. The company targets the IGF-1R pathway, which plays a role in thyroid eye disease (TED). Revenue, if achieved, would come from eventual drug approvals, partnerships, or licensing arrangements. Until then, the company relies on capital markets to fund operations and trials.
Viridian Therapeutics was founded in 2014 and is headquartered in Waltham, Massachusetts.
- VRDN-001: humanized anti-IGF-1R antibody in Phase 1/2 trials for thyroid eye disease
- VRDN-002: IGF-1R antibody in Phase 1 clinical development
- VRDN-003: therapeutic antibody targeting IGF-1R for thyroid eye disease treatment
Is VRDN a Good Stock to Buy?
UQS Score rates VRDN as Below Average overall, reflecting the realities of early-stage biotech investing.
The Growth pillar stands out as the clearest positive signal — Viridian's pipeline activity and clinical advancement place it among more active development-stage peers. The Risk pillar also rates Good, suggesting the company's financial runway and balance sheet position are relatively managed for a pre-revenue biotech.
Quality and Moat both rate Weak, which is typical for clinical-stage companies with no approved products and limited defensible competitive positioning yet. Valuation rates Elevated, meaning the market may already be pricing in optimistic pipeline outcomes.
See the full pillar breakdown and underlying financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does VRDN pay dividends?
No — Viridian Therapeutics, Inc. does not currently pay a dividend.
Viridian Therapeutics does not pay a dividend, which is standard for clinical-stage biotechnology companies. All available capital is directed toward funding clinical trials and pipeline development. Investors in VRDN are typically seeking potential capital appreciation tied to drug development milestones rather than income.
When does VRDN report earnings?
Viridian Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue biotech, quarterly results focus on cash burn, operating expenses, and clinical trial progress rather than sales or profit metrics. Pipeline updates and trial readouts tend to drive more market attention than the income statement alone.
For the most recent quarter's results and pipeline updates, visit Viridian Therapeutics' investor relations page directly.
VRDN Price History
-20.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Viridian Therapeutics, Inc.?
Based on Viridian Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
VRDN Long-term Outlook
Viridian's fundamental outlook is shaped by its Strong Growth pillar and Good Risk profile, offset by Weak Quality and Moat ratings. The path forward depends heavily on clinical trial outcomes for its IGF-1R antibody candidates. Positive data readouts could meaningfully shift the company's profile, while setbacks would pressure the already Elevated Valuation. The risk-reward dynamic here is asymmetric — characteristic of early-stage biotech.
Growth drivers
- Advancement of VRDN-001 through Phase 1/2 trials toward potential pivotal study design
- Expanding the IGF-1R antibody platform across multiple thyroid eye disease indications
- Potential partnership or licensing deals that could validate the pipeline and provide non-dilutive capital
Key risks
- Clinical trial failure or disappointing efficacy data could sharply reset valuation expectations
- Elevated Valuation pillar suggests limited margin of safety if pipeline progress slows
- Ongoing cash burn without commercial revenue creates dependence on future capital raises
VRDN vs Peers
Viridian operates in a competitive ophthalmology and rare disease biotech space alongside several other development-stage and specialty companies.
EyePoint focuses on sustained-release drug delivery for eye diseases, competing in the ophthalmology space with a different therapeutic approach than Viridian's antibody platform.
Iovance pursues tumor-infiltrating lymphocyte cell therapies for cancer, representing a different modality but competing for similar biotech investor capital and attention.
Inhibrx develops engineered protein therapeutics across multiple rare disease areas, sharing the clinical-stage biotech profile and IGF-pathway-adjacent competitive landscape.
Frequently Asked Questions
What does Viridian Therapeutics do?
Viridian Therapeutics is a clinical-stage biotechnology company developing monoclonal antibody therapies targeting the IGF-1R pathway. Its primary focus is thyroid eye disease (TED), with three pipeline candidates — VRDN-001, VRDN-002, and VRDN-003 — at various stages of early clinical development. The company has no approved products or commercial revenue at this time.
Does VRDN pay dividends?
No, Viridian Therapeutics does not pay a dividend. As a pre-revenue clinical-stage biotech, the company reinvests all available capital into its pipeline and clinical operations. Dividend payments are not typical for companies at this stage of development.
When does VRDN report earnings?
Viridian Therapeutics follows a standard quarterly reporting cadence for US-listed companies. For the exact timing of upcoming earnings releases, check the investor relations section of the company's official website.
Is VRDN a good stock to buy?
UQS Score rates VRDN as Below Average overall. The Growth pillar is Strong and Risk rates Good, but Quality and Moat are both Weak, and Valuation is Elevated. Whether VRDN fits a portfolio depends on an investor's risk tolerance for clinical-stage biotech exposure. The full pillar breakdown is available to Pro members.
Is VRDN overvalued?
The UQS Valuation pillar for VRDN rates as Elevated, suggesting the current market price may reflect optimistic assumptions about pipeline success. For a pre-revenue biotech, valuation is inherently forward-looking and sensitive to clinical data outcomes. Investors should weigh this against the company's development timeline.
How does VRDN compare to its competitors?
Viridian competes in the ophthalmology and rare disease biotech space alongside companies like EyePoint Pharmaceuticals, Iovance Biotherapeutics, and Inhibrx Biosciences. Each pursues different therapeutic modalities and indications. UQS Score provides side-by-side pillar comparisons for Pro members looking to evaluate VRDN against peers.
What is VRDN's market cap bracket?
Viridian Therapeutics is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to mid- or large-cap peers, but may also offer greater upside potential if clinical milestones are achieved.
Who founded Viridian Therapeutics?
Viridian Therapeutics was originally founded in 2014. The company was formerly known as Miragen Therapeutics before rebranding to Viridian Therapeutics in January 2021. Founding details are publicly available through the company's official filings and investor relations materials.
Is VRDN a long-term quality investment?
From a long-term quality standpoint, VRDN's UQS profile shows meaningful gaps — Quality and Moat both rate Weak, which reflects the absence of approved products, recurring revenue, or durable competitive advantages at this stage. The Strong Growth pillar indicates pipeline momentum, but long-term quality indicators would need to improve as the company matures.
What is the main competitive advantage of Viridian Therapeutics?
Viridian's differentiation centers on its IGF-1R antibody platform and its focus on thyroid eye disease, a condition with limited treatment options. However, the UQS Moat pillar rates Weak, reflecting that competitive advantages for a pre-revenue biotech are difficult to establish until products reach the market and demonstrate clinical superiority.
Is VRDN a growth stock or value stock?
VRDN leans firmly toward the growth category. Its UQS Growth pillar is Strong, reflecting active pipeline development and clinical advancement. However, the Valuation pillar rates Elevated, meaning investors are paying a premium for that growth potential — a common dynamic in clinical-stage biotech.
Unlock Full VRDN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown for VRDN
- ✓Access underlying financial metrics driving each pillar rating
- ✓Compare VRDN side-by-side with ophthalmology and biotech peers
- ✓Track Quality, Moat, and Valuation signals as the pipeline evolves
- ✓Get the full analyst view available exclusively to Pro members
Pro Analysis
VRDN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 34.6 | 3.3 | 19.0 | 91.0 | 72.1 | 0.0 | +0.2 |
| Apr 2, 2026 | 34.4 | 3.3 | 19.0 | 91.0 | 70.8 | 0.0 | — |
VRDN — Pillar Breakdown
Quality
— 3.3/100 (25%)Viridian Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 91.0/100 (20%)Viridian Therapeutics, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 72.1/100 (15%)Viridian Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Viridian Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 19/100 (25%)Viridian Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for VRDN.
Score Composition
Financial Data
More Stock Analysis
How is the VRDN UQS Score Calculated?
The UQS (Unified Quality Score) for Viridian Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Viridian Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Viridian Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.